Skip to main content

Jim Dentzer

Equibles does not estimate personal net worth.

Get an email with a short summary when Curis Inc publishes a filing, an earnings call transcript or a press release.

Get CRIS alerts

About Jim Dentzer

Jim Dentzer is recorded as CEO at Curis Inc (CRIS). Jim Dentzer has spoken on 15 earnings calls across 1 company, most recently for Curis Inc on November 12, 2026. Curis Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Curis Inc includes James E. Dentzer (CEO and Board Member), Martyn D. Greenacre (Chairman and Board Member), William E. Steinkrauss (CFO) and 7 others.

Jim Dentzer on recent calls

“I'll start with PCNSL, our lead program and first NHL study. We continue to make steady progress in our TIC-AIM lymphoma study in primary CNS lymphoma. One of the most rare and most difficult to treat of the NHL subtypes.”
CEO, Curis Inc Q3 FY2026 Earnings Call ·
“I'd like to start this quarter's call by welcoming Dr. Ahmed Hamdy to the Curis Executive team. Dr. Hamdy is a well-known and respected leader in the industry and brings a wealth of experience as the CMO of Pharmacyclics, Founder and CMO of Acerta, and Founder and CEO of Vincerx.”
CEO, Curis Inc Q1 FY2025 Earnings Call ·
“Let's start with our TakeAim Leukemia Study, which is evaluating emavusertib in combination with ibrutinib in relapsed/refractory PCNSL patients that have failed after treatment with a BTK inhibitor.”
CEO, Curis Inc Q3 FY2024 Earnings Call ·
“Let’s start with our TakeAim Lymphoma study, which is evaluating emavusertib in combination with ibrutinib in relapsed/refractory PCNSL patients that have failed after treatment with a BTK inhibitor.”
CEO, Curis Inc Q2 FY2024 Earnings Call ·
“I'd like to start today's call with a look back over the past 12 months. Entering 2023, the whole biotech industry was struggling in the headwinds of a challenging financial market.”
CEO, Curis Inc Q4 FY2023 Earnings Call ·

Affiliation history

Company network

Leadership on record at Curis Inc

Recent activity